Press Release: Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage compan

Dow JonesApr 30 20:00

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

PDF Version SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients

Akero TherapeuticsApr 30 12:00

B of A Securities: Reiterates Akero Therapeutics' (AKRO.US) neutral rating with a target price of $30.00.

B of A Securities: Reiterates Akero Therapeutics' (AKRO.US) neutral rating with a target price of $30.00.

Zhitong FinanceApr 22 18:31

B of A Securities Reinstates Neutral on Akero Therapeutics, Announces $30 Price Target

B of A Securities analyst Alexandria Hammond reinstates Akero Therapeutics with a Neutral and announces $30 price target.

Analyst UpgradesApr 22 18:21

Akero Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 44.51% B of A Securities → $30 Reinstates → Neutral 03/05/2024 102.31% UBS $39 → $42 Maintains

BenzingaApr 22 18:20

Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints

Seeking AlphaApr 20 05:10